Sifalimumab
- CAS No.
- 1006877-41-3
- Chemical Name:
- Sifalimumab
- Synonyms
- Sifalimumab;MDX-1103|||MEDI-545;Sifalimumab (anti-IFNa1);Research Grade Sifalimumab;Research Grade Sifalimumab(DHB94501)
- CBNumber:
- CB28080806
- Molecular Formula:
- Molecular Weight:
- 0
- MDL Number:
- MOL File:
- Mol file
- MSDS File:
- SDS
- TDS File:
- TDS
| form | Liquid |
|---|---|
| color | Colorless to light yellow |
| FDA UNII | XOY1YA7RMC |
Sifalimumab price
| Manufacturer | Product number | Product description | CAS number | Packaging | Price | Updated | Buy |
|---|---|---|---|---|---|---|---|
| ChemScene | CS-0612926 | Sifalimumab 99.46% | 1006877-41-3 | 1mg | $379 | 2026-06-04 | Buy |
| ChemScene | CS-0612926 | Sifalimumab 99.46% | 1006877-41-3 | 5mg | $1016 | 2026-06-04 | Buy |
| ChemScene | CS-0612926 | Sifalimumab 99.46% | 1006877-41-3 | 10mg | $1625 | 2026-06-04 | Buy |
| aablocks | AA0294SD | Sifalimumab | 1006877-41-3 | 1mg | $258 | 2026-06-02 | Buy |
| aablocks | AA0294SD | Sifalimumab | 1006877-41-3 | 5mg | $643 | 2026-06-02 | Buy |
Sifalimumab Chemical Properties, Uses, Production
Uses
Sifalimumab (MEDI-545) is an anti-IFNα monoclonal antibody. Sifalimumab suppresses the abnormal immune activity by binding to multiple interferon-alpha (IFNα) subtypes. Sifalimumab can be used in systemic lupus erythematosus (SLE) research[1][2].
in vivo
Sifalimumab (subcutaneous injection; 30 mg/kg and 3 μg/g) treatment shows therapeutic effect and attenuates the lymphocyte infiltration[2].
| Animal Model: | Wild-type male BALB/c mice[2] |
| Dosage: | 30 mg/kg and 3 μg/g |
| Administration: | Subcutaneous injection; 30 mg/kg and 3 μg/g |
| Result: | Prevented the increase CpG-induced, decreasing CD86 fluorescence intensity by 1.9-fold (P < 0.05). Showed a potentially therapeutic effect attenuating the CpG-induced lymphocyte infiltration. Attenuated the CD45 increase (P<0.05). |
References
[1] Merrill JT, et al. Safety profile and clinical activity of sifalimumab, a fully human anti-interferon α monoclonal antibody, in systemic lupus erythematosus: a phase I, multicentre, double-blind randomised study. Ann Rheum Dis. 2011 Nov;70(11):1905-13. DOI:10.1136/ard.2010.144485
[2] La Maestra S, et al. Brain microglia activation induced by intracranial administration of oligonucleotides and its pharmacological modulation. Drug Deliv Transl Res. 2018 Oct;8(5):1345-1354. DOI:10.1007/s13346-018-0535-3
Sifalimumab Preparation Products And Raw materials
Raw materials
Preparation Products
Sifalimumab Suppliers
| Supplier | Tel | Country | ProdList | Advantage | |
|---|---|---|---|---|---|
| Shanghai YuanYe Biotechnology Co., Ltd. | 15026964105 | 2881489226@qq.com | China | 89667 | 60 |
| ShangHai Biochempartner Co.,Ltd | 177-54423994 17754423994 | 2853530910@QQ.com | China | 8000 | 62 |
| TargetMol Chemicals Inc. | +1-781-999-5354; +1-00000000000 | marketing@targetmol.com | United States | 32431 | 58 |
| Guangzhou Hongyuan Chemical Co.,Ltd | 15817493340 | 981810490@qq.com | China | 1577 | 58 |
| Wuhan Chemstan Biotechnology Co., Ltd. | 027-65317797 15926423062 | 422450190@qq.com | China | 10305 | 58 |
| Beijing Jin Ming Biotechnology Co., Ltd. | 010-60605840 | psaitong@jm-bio.com | China | 27626 | 58 |
| TargetMol Chemicals Inc. | 4008200310 15002144251 | marketing@tsbiochem.com | China | 24951 | 58 |
| Biolab Reagents | 027-65279366 18108604356 | products@biolabreagent.com | China | 9864 | 58 |
| Wuhan Jingkangen Biomedical Technology Co., Ltd | 13720134139 086-15871494362 13720134139 | orders@jknbiochem.com | China | 7283 | 58 |
| Shanghai Yifei Biotechnology Co. , Ltd. | 021-65675885 18964387627 | customer_service@efebio.com | China | 11963 | 58 |
View Latest Price from Sifalimumab manufacturers
| Image | Update time | Product | Price | Min. Order | Purity | Supply Ability | Manufacturer | |
|---|---|---|---|---|---|---|---|---|
 |
2026-07-27 | Sifalimumab
1006877-41-3
|
$297.00-1230.00 | 100% (SEC-HPLC) | 10g | TargetMol Chemicals Inc. |
-
- Sifalimumab
1006877-41-3
- $297.00-1230.00
- 100% (SEC-HPLC)
- TargetMol Chemicals Inc.
